Purging human ovarian cortex of contaminating leukaemic cells by targeting the mitotic catastrophe signalling pathway
Open Access
- 16 March 2021
- journal article
- research article
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 38 (6) , 1571-1588
Abstract
Purpose: Is it possible to eliminate metastasised chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML) cells from ovarian cortex fragments by inhibition of Aurora B/C kinases (AURKB/C) without compromising ovarian tissue or follicles? Methods: Human ovarian cortex tissue with experimentally induced tumour foci of CML, AML and primary cells of AML patients were exposed to a 24h treatment with 1 μM GSK1070916, an AURKB/C inhibitor, to eliminate malignant cells by invoking mitotic catastrophe. After treatment, the inhibitor was removed, followed by an additional culture period of 6 days to allow any remaining tumour cells to form new foci. Ovarian tissue integrity after treatment was analysed by four different assays. Appropriate controls were included in all experiments. Results: Foci of metastasised CML and AML cells in ovarian cortex tissue were severely affected by a 24h ex vivo treatment with an AURKB/C inhibitor, leading to the formation of multi-nuclear syncytia and large-scale apoptosis. Ovarian tissue morphology and viability was not compromised by the treatment, as no significant difference was observed regarding the percentage of morphologically normal follicles, follicular viability, glucose uptake or in vitro growth of small follicles between ovarian cortex treated with 1 μM GSK1070916 and the control. Conclusion: Purging of CML/AML metastases in ovarian cortex is possible by targeting the Mitotic Catastrophe Signalling Pathway using GSK1070916 without affecting the ovarian tissue. This provides a therapeutic strategy to prevent reintroduction of leukaemia and enhances safety of autotransplantation in leukaemia patients currently considered at high risk for ovarian involvement.Keywords
Funding Information
- Merck KGaA (A19-1294)
This publication has 84 references indexed in Scilit:
- The dormant and the fully competent oocyte: comparing the transcriptome of human oocytes from primordial follicles and in metaphase IIMolecular Human Reproduction, 2013
- Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAPGenes & Development, 2012
- Aurora kinase inhibitors: Progress towards the clinicInvestigational New Drugs, 2012
- Safety of Ovarian Tissue Autotransplantation for Cancer PatientsObstetrics and Gynecology International, 2011
- Glucose/lactate metabolism of cryopreserved intact bovine ovaries as a novel quantitative marker to assess tissue cryodamageReproductive BioMedicine Online, 2011
- High Chromosome Number in hematological cancer cell lines is a Negative Predictor of Response to the inhibition of Aurora B and C by GSK1070916Journal of Translational Medicine, 2011
- Aurora kinase A is a target of Wnt/β-catenin involved in multiple myeloma disease progressionBlood, 2009
- Ligand Bound β1 Integrins Inhibit Procaspase-8 for Mediating Cell Adhesion-Mediated Drug and Radiation Resistance in Human Leukemia CellsPLOS ONE, 2007
- The cellular geography of Aurora kinasesNature Reviews Molecular Cell Biology, 2003
- Germinal vesicle breakdown in oocytes of human atretic follicles during the menstrual cycleReproduction, 1986